CCL2, CCL3 and CCL5 chemokines in systemic sclerosis: The correlation with SSc clinical features and the effect of prostaglandin E1 treatment

Clinical and Experimental Rheumatology

Volumn 30, Issue SUPPL.71, 2012, Pages

  Bandinelli, Francesca ^a   Del Rosso, Angela ^a   Gabrielli, Armando ^b   Giacomelli, Roberto ^c   Bartoli, Francesca ^a   Guiducci, Serena ^a   Matucci Cerinic, Marco ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Chemokines; MCP1 CCL2; MIP1 CCL3; Prostaglandin E1; RANTES CCL5; Skin score; Systemic sclerosis

Indexed keywords

LEICLODEDRIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROSTAGLANDIN E1; PROSTAVASIN; RANTES; SCL 70 ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; ARTICLE; CALCINOSIS; CAPILLAROSCOPY; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE DURATION; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FINGER ULCER; HEART DISEASE; HUMAN; LUNG DISEASE; MALE; MOLECULAR PATHOLOGY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SKIN ULCER; SYSTEMIC SCLEROSIS;

AGED; ALPROSTADIL; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHEMOKINE CCL2; CHEMOKINE CCL3; CHEMOKINE CCL5; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84867389057     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. DISTLER O, PAP T, KOWAL-BIELECKA O et al.: Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum 2001; 44: 2665-78.
2. HASEGAWA M, SATO S, TAKEHARA K: Augmented production of chemokines (MCP-1, MIP1a, and MIP1ß) in patients with systemic sclerosis: MCP-1 and MIP1a may be involved in the development of pulmonary fibrosis. Clin Exp Immunol 1999; 117: 159-65.
3. DISTLER JH, AKHMETSHINA A, SCHETT G, DISTLER O: Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis. Rheumatology (Oxford) 2009; 48: 98-103.
4. ZHANG Y, MCCORMICK LL, DESAI SR. WU C, GILLIAM AC: Murine sclerodermatous graft versus host disease, a model for human scleroderma: cutaneous cytokines, chemokines and immune cell activation. J Immunol 2002; 168: 3088-98.
5. SATO S: Abnormalities of adhesion molecules and chemokines in scleroderma. Curr Opin Rheumatol 1999; 11: 503.
6. CHUJO S, SHIRASAKI F, KONDO-MIYAZAKI M, IKAWA Y, TAKEHARA K: Role of connective tissue growth factor and its interaction with basic fibroblast growth factor and macrophage chemoattractant protein-1 in skin fibrosis. J Cell Physiol 2009; 220: 189-95.
7. HOGABOAM CM, STEINHAUSEN ML, CHENSUE SW, KUNKEL SL: Novel roles for chemokines and fibroblasts in interstitial fibrosis. Kidney Int 1998; 54: 2152-9.
8. UGUCCIONI M, D'APUZZO M, LOETSCHER M, DEWALD B, BAGGIOLINI M: Action of the chemotactic cytokines MCP1/CCL2, MCP2, MCP3, RANTES/CCL5, MIPA1α and MIPA1β on human monocytes. Eur J Immunol 1995; 25: 64.
9. ZHANG Y, MCCORMICK LL, DESAI SR. WU C, GILLIAM AC: Murine sclerodermatous graft versus host disease, a model for human scleroderma: cutaneous cytokines, cemokines and immune cell activation. J Immunol 2002; 168: 3088-98.
10. DISTLER O, RINKES B, HOHENLEUTERNER U et al.: Expression of RANTES/CCL5 in biopsies of skin and upper gastrointestinal tract from patients with systemic sclerosis. Rheumatol Int 1999; 19: 39-46.
11. SILVER RM: Interstitial lung disease of systemic sclerosis. Int Rev Immunol 1995; 12: 281-91.
12. BOLSTER MB, LUDWICKA A, SUTHERLAND SE, STRANGE C, SILVER RM: Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum 1997; 40: 743-51.
13. LUZINA IG, ATAMAS SP, WISE R, WIGLEY FM, XIAO HQ, WHITE B: Gene expression in bronchoalveolar lavage cells from scleroderma patients. Am J Respir Cell Mol Biol 2002; 26: 549-57.
14. RIEMEKASTEN G, SUNDERKÖTTER C: Vasoactive therapies in systemic sclerosis.Rheumatology (Oxford) 200; 45 (Suppl. 3): iii49-51.
15. DOWD PM, KOVACS IB, BLAND CJ, KIRBY JD: Effect of prostaglandins I2 and E1 on red cell deformability in patients with Raynaud's phenomenon and systemic sclerosis. Br Med J (Clin Res Ed) 1981; 283: 350.
16. WEISS C, REGELE S, VELICH T, BARTSCH P, WEISS T: Hemostasis and fibrinolysis in patients with intermittent claudication: effects of prostaglandin E1. Prostaglandin Leukotrien Essential Fatty Acids 2000; 63: 271-7.
17. BANDINELLI F, BARTOLI F, PERFETTO E et al.: The fibrinolytic system components are increased in systemic sclerosis and modulated by Alprostadil (alpha1 ciclodestrin). Clin Exp Rheumatol 2005; 23: 671-7.
18. GARDINALI M, POZZI MR, BERNAREGGI M et al.: Treatment of Raynaud's phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis. J Rheumatol 2001; 28: 786-94.
19. SUBCOMMITTEE FOR SCLERODERMA CRITERIA OF THE AMERICAN RHEUMATISM ASSOCIATION DIAGNOSTIC AND THERAPEUTIC CRITERIA COMMITTEE: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
20. LEROY EC, BLACK CM, FLEISCHMAJER R et al.: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
21. CUTOLO M, SULLI A, PIZZORNI C, ACCARDO S: Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol 2000; 27: 155-60.
22. CLEMENTS P, LACHENBRUCH P, SEIBOLD J et al.: Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281-5.
23. KARRER S, BOSSERHOFF AK, WEIDERER P et al.: The _2518 promotor polymorphism in the MCP-1 gene is associated with systemic sclerosis. J Invest Dermatol 2005; 124: 92-8.
24. EUN BL, JINYING Z, JEONG YK, MOMIAO X, YEONG WS: Evidence of potential interaction of chemokine genes in susceptibility to systemic sclerosis. Arthritis Rheum 2007; 56: 2443-8.
25. PETERLANA D, PUCCETTI A, CARAMASCHI P et al.: Endothelin-1 serum levels correlate with MCP-1 but not with homocysteine plasma concentration in patients with systemic sclerosis. Scand J Rheumatol 2006; 35: 133-7.
26. MATSUSHITA T, HASEGAWA M, HAMAGUCHI Y, TAKEHARA K, SATO S: Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol 2006; 33: 275-8.
27. ANTONELLI A, FERRI C, FALLAHI P et al.: CXL110 (a) and CCL2 (ß) chemokines in sistemi sclerosis- a longitudinal study. Rheumatology 2008; 47: 45-9.
28. HASEGAWA M, FUJIMOTO M, MATSUSHITA T, HAMAGUCHI Y, TAKEHARA K, SATO S: Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis. Clin Rheumatol 20101; 30: 231-7.
29. YAMAMOTO T, NISHIOKA K: Role of monocyte chemoattractant protein 1 and its receptor CCR2 in the pathogenesis of bleomycin induced scleroderma. J Invest Dermatol 2003; 121: 510-6.
30. KARPUS WJ, LUKACS NW, KENNEDY KJ, SMITH WS, HURST SD, BARRETT TA: Differential CC chemokine-induced enhancement of t helper cell cytokine production. J Immunol 1997; 158: 4129-36.
31. ANTONELLI A, FERRI C, FALLAHI P et al.: Th1 and Th2 chemokine serum levels in systemic sclerosis in the presence or absence of autoimmune tyroiditis. J Rheumatol 2008; 35: 1809-11.
32. ZHOU L, ASKEW D, WU C, GILLIAM AC: Cutaneous gene expression by DNA microarray in murine sclerodermatous graft-versushost disease, a model for human scleroderma. J Invest Dermatol 2007; 127: 281-92.
33. CARULLI MT, HANDLER C, COCHLENAD JG, BLACK CM, DENTON CP: Can CCL2 serum levels be used in risk stratification or to monitor treatment response in systemic sclerosis. Ann Rheum Dis 2008; 67: 105-9.
34. SICINSKA J, GORSKA E, CICHA M et al.: Increased serum fractalkine in systemic sclerosis. Down-regulation by prostaglandin E1. Clin Exp Rheum 2008; 26: 27-533.
35. INAOKI M, SATO S, TAKEHARA K: Elevated serum levels of soluble L-selectin in patients with systemic sclerosis declined after intravenous injection of lipo-prostaglandin E1. J Dermatol Sci 2001: 25: 78-82.
36. NEY P, HECKER G, SCHRODER H, SCHROR K: Potent inhibition of leukotriene (LT) B4 release from human polymorphonuclear leukocytes (PMN) by the PGE1-analogue OP-1206. Biomed Biochim Acta 1988; 47: S186-9.
37. SCHROR K, HECKER G: Potent inhibition of superoxide anion generation by PGE1 and the PGE1 analogue OP-1206 in human PMNs--unrelated to its antiplatelet PGI2-like activity. Vasa Suppl 1987; 17: 11-6.
38. ZHOU LJ, INOUE M, GUNJI H, ONO I, KANEKO F: Effect of prostaglandin E1 on cultured dermal fibroblasts. J Dermatol Sci 1997; 14: 217-24.